Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin’s lymphoma models and in cells deficient in DNA damage repair

PDF  |  How to cite

Oncotarget. 2023; 14:722-722. https://doi.org/10.18632/oncotarget.28479

Metrics: PDF 439 views  |   ?  

Jianli Zhou1, Drew Sturtevant1, Cassie Love2, Aditya Kulkarni1, Neha Biyani1, Umesh Kathad1, Elizabeth Thacker3, Sandeep Dave2 and Kishor Bhatia1

1Lantern Pharma Inc., Plano, TX 75024, USA
2Department of Medicine, Duke University, Durham, NC 27708, USA
3Data Driven Bioscience, Durham, NC 27707, USA

Published: July 20, 2023

Copyright: © 2023 Zhou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Wet-lab experiments conducted at Data Driven Bioscience, Rincon Biosciences, Reprocell Inc., intoDNA, and Toxys Europe were funded by Lantern Pharma Inc.

Original article: Oncotarget. 2023; 14:597-611. DOI: https://doi.org/10.18632/oncotarget.28454.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28479